363 results on '"van Zandwijk, Nico"'
Search Results
2. Asbestos-Related lung Cancer: An underappreciated oncological issue
3. Asbestos history and use
4. Circulating tumor cell detection may offer earlier diagnosis in patients suspected of asbestos-related lung cancer
5. Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
6. Patterns of care and survival of older patients with malignant pleural mesothelioma
7. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data
8. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma
9. Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies
10. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
11. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
12. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study
13. Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009
14. Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
15. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009
16. Exon 20-Mutated NSCLC: Extending the Data Set to Allow the Recognition of Potential Causes
17. A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
18. Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma
19. Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board
20. Malignant pleural mesothelioma
21. The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma
22. A multidisciplinary review of several aspects of Asbestos-Related Lung Cancer (ARLC)
23. Circulating microRNAs: Association with disease and potential use as biomarkers
24. The silent malignant mesothelioma epidemic: a call to action.
25. Asbestos‐related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation.
26. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: Why pneumonectomy should be avoided
27. TARGETED DELIVERY OF A SYNTHETIC MICRORNA MIMIC AS AN APPROACH TO CANCER TREATMENT: O3
28. A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma
29. MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma
30. Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care
31. Update in lung cancer: Prologue to a modern review series
32. Immunotherapy in Non–Small-Cell Lung Carcinoma: From Inflammation to Vaccination
33. Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma
34. Health-related quality of life and inflammatory markers in malignant pleural mesothelioma
35. CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone
36. Does miR-1 Play a Role in Malignant Pleural Mesothelioma Development and Progression?
37. ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma
38. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
39. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA
40. Mapping of treatment-induced apoptosis in normal structures: 99mTc-Hynic-rh-annexin V SPECT and CT image fusion
41. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review
42. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing
43. Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma
44. Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
45. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma
46. Molecular biomarkers in malignant mesothelioma: state of the art
47. Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma
48. Validation of tissue microarray technology in malignant pleural mesothelioma
49. Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study
50. The Influence of Fluticasone Inhalation on Markers of Carcinogenesis in Bronchial Epithelium
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.